» Articles » PMID: 12734426

Multistep Carcinogenesis: a Chain Reaction of Aneuploidizations

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2003 May 8
PMID 12734426
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Carcinogenesis is a multistep process in which new, parasitic and polymorphic cancer cells evolve from a single, normal diploid cell. This normal cell is converted to a prospective cancer cell, alias "initiated", either by a carcinogen or spontaneously. The initiated cell typically does not have a new distinctive phenotype yet, but evolves spontaneously--over months to decades--to a clinical cancer. The cells of a primary cancer also evolve spontaneously towards more and more malignant phenotypes. The outstanding genotype of initiated and cancer cells is aneuploidy, an abnormal balance of chromosomes, which increases and varies in proportion with malignancy. The driving force of the spontaneous evolution of initiated and cancerous cells to ever more abnormal phenotypes is said to be their "genetic instability". However, since neither the instability of cancer phenotypes nor the characteristically slow kinetics of carcinogenesis are compatible with gene mutation, we propose here that the driving force of carcinogenesis is the inherent instability of aneuploid karyotypes. Aneuploidy renders chromosome structure and segregation error-prone, because it unbalances mitosis proteins and the many teams of enzymes that synthesize and maintain chromosomes. Thus, carcinogenesis is initiated by a random aneuploidy, which is induced either by a carcinogen or spontaneously. The resulting karyotype instability sets off a chain reaction of aneuploidizations, which generate ever more abnormal and eventually cancer-specific combinations and rearrangements of chromosomes. According to this hypothesis the many abnormal phenotypes of cancer are generated by abnormal dosages of thousands of aneuploid, but un-mutated genes.

Citing Articles

The Interaction of Human Papillomavirus Infection and Prostaglandin E Signaling in Carcinogenesis: A Focus on Cervical Cancer Therapeutics.

Garcia-Quiroz J, Vazquez-Almazan B, Garcia-Becerra R, Diaz L, Avila E Cells. 2022; 11(16).

PMID: 36010605 PMC: 9406919. DOI: 10.3390/cells11162528.


Upregulation of anaphase promoting complex (APC) 7 as a prognostic marker for esophageal squamous cell carcinoma: A hospital based study.

Ali E, Kalita M, Kalita S, Talukdar J, Deka A, Sultana J Heliyon. 2022; 8(6):e09722.

PMID: 35761933 PMC: 9233225. DOI: 10.1016/j.heliyon.2022.e09722.


Congenital Aneuploidy in Klinefelter Syndrome with B-Cell Acute Lymphoblastic Leukemia Might Be Associated with Chromosomal Instability and Reduced Telomere Length.

Kjeldsen E Cancers (Basel). 2022; 14(9).

PMID: 35565445 PMC: 9136641. DOI: 10.3390/cancers14092316.


The multifaceted roles of cohesin in cancer.

Di Nardo M, Pallotta M, Musio A J Exp Clin Cancer Res. 2022; 41(1):96.

PMID: 35287703 PMC: 8919599. DOI: 10.1186/s13046-022-02321-5.


Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance.

Lawal B, Tseng S, Olugbodi J, Iamsaard S, Ilesanmi O, Mahmoud M Cancers (Basel). 2021; 13(16).

PMID: 34439277 PMC: 8394789. DOI: 10.3390/cancers13164124.